Explore 3 Stock Ideas & Industry Insights Download Free Report

Acrivon Therapeutics, Inc. Common Stock

Company price
1.4799 USD 0.02 ( 1.36%)
Last update at 2026-11-17T15:11:00Z
VOLUME
121790
Market Cap
78.42M

Momentum Score

…

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.39
Low
1.56
High
52 Week Price Range
1.27
Low
3.56
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.46
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.02
ROE
-64.63%
Net Debt
-38.79M
ROCE
-73.75%
Diluted EPS TTM
-1.88

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -77.91M -80.56M -60.39M -31.17M -16.24M
Net income -77.91M -80.56M -60.39M -29.68M -16.24M
Selling general administrative 24.12M 25.21M 21.08M 8.71M 2.47M
Selling and marketing expenses - - 0.13M - -
Gross profit -1.36M -1.01M -0.54M - -
Reconciled depreciation 1.36M 1.01M 0.51M 0.36M 0.04M
Ebit -84.11M -80.56M -60.39M -33.02M -16.18M
Ebitda -82.76M -79.55M -59.85M -32.66M -16.15M
Depreciation and amortization 1.36M 1.01M 0.54M 0.36M 0.04M
Non operating income net other - - - 1.49M -
Operating income -84.11M -89.20M -67.24M -32.66M -16.18M
Other operating expenses 84.11M 89.20M 67.24M 32.66M 16.18M
Interest expense - - - -1.49M 0.06M
Interest income 6.48M 9.20M 7.04M - -
Net interest income 6.48M 9.20M 7.04M - -
Income tax expense - - 0.00M -1.49M 0.06M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 82.76M 88.19M 66.70M 32.66M 16.18M
Cost of revenue 1.36M 1.01M 0.54M - -
Total other income expense net 6.21M 8.64M 6.85M 1.49M -0.06M
Net income from continuing ops -77.91M -80.56M -50.06M -31.17M -16.24M
Net income applicable to common shares - - - -31.17M -16.24M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 129.72M 196.59M 138.26M 181.23M 106.59M
Other current assets 1.86M 2.15M 2.23M 4.34M 0.81M
Total liab 17.20M 19.80M 17.07M 10.75M 130.40M
Total stockholder equity 112.52M 176.79M 121.19M 170.47M -23.81M
Other current liab 12.21M 15.40M 7.38M 4.82M 1.22M
Common stock 0.03M 0.03M 0.02M 0.02M 0.00M
Capital stock 0.03M 0.03M 0.02M 0.02M 0.00M
Retained earnings -274.88M -196.98M -116.42M -56.03M -24.86M
Other assets - - 0.00M 0.39M 0.39M
Cash 41.50M 39.82M 36.02M 29.52M 99.60M
Total current liabilities 15.66M 17.21M 13.30M 6.52M 2.91M
Current deferred revenue - - - 0.07M 0.07M
Net debt -38.79M -36.17M -31.37M -24.56M -93.97M
Short term debt 1.17M 1.06M 0.88M 0.73M 0.66M
Short long term debt total 2.71M 3.65M 4.64M 4.96M 5.63M
Other stockholder equity 387.25M 373.28M 237.68M 45.35M 1.05M
Property plant equipment - - - 2.09M 5.79M
Total current assets 120.44M 181.63M 129.69M 127.75M 100.41M
Long term investments 0.00M 5.09M 0.00M 41.88M -
Net tangible assets - - - 170.47M -23.81M
Short term investments 77.08M 139.66M 91.44M 98.23M -
Accounts payable 2.28M 0.76M 5.05M 0.90M 0.96M
Accumulated other comprehensive income 0.11M 0.45M -0.08M -0.10M -
Common stock total equity - - - 0.02M -
Retained earnings total equity - - - -56.03M -
Non currrent assets other 1.86M 1.84M 0.25M 4.73M 0.39M
Non current assets total 9.27M 14.96M 8.57M 53.48M 6.18M
Capital lease obligations 2.71M 3.65M 4.64M 4.96M 5.63M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 67.77M -51.77M -64.89M -139.51M -0.24M
Change to liabilities - - - -0.24M 0.80M
Total cashflows from investing activities 66.10M -51.77M 50.72M -141.68M -0.24M
Total cash from financing activities -0.75M 121.03M -1.55M 101.71M 112.22M
Change to operating activities - - - - -0.47M
Net income -77.91M -80.56M -60.39M -31.17M -16.24M
Change in cash 1.69M 3.59M 6.52M -70.08M 98.00M
Begin period cash flow 40.02M 36.43M 29.91M 99.99M 1.99M
End period cash flow 41.70M 40.02M 36.43M 29.91M 99.99M
Total cash from operating activities -63.66M -65.67M -42.64M -30.12M -13.98M
Issuance of capital stock 0.00M 70.00M 0.00M 104.46M 112.22M
Depreciation 0.92M 1.01M 0.54M 0.36M 0.04M
Sale purchase of stock - - - 101.71M -
Other cashflows from financing activities -0.75M 51.03M -1.30M -2.75M -0.24M
Change to netincome - - - 2.19M 1.90M
Capital expenditures 1.67M 2.77M 1.29M 2.17M 0.24M
Cash flows other operating - - - -0.56M -
Cash and cash equivalents changes - - - -70.08M -
Change in working capital -2.43M 2.44M 8.14M -1.53M 0.33M
Stock based compensation 14.72M 14.29M 11.62M 2.19M 0.50M
Other non cash items 1.03M -2.85M 1.06M 0.03M 1.14M
Free cash flow -65.33M -68.44M -43.93M -32.28M -14.22M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ACRV
Acrivon Therapeutics, Inc. Common Stock
0.02
1.36%
1.48 - - - 0.97 -0.43
NVO
Novo Nordisk A/S
-1.21
2.90%
40.40 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-6.15
1.14%
531.64 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
4.70
0.49%
957.10 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

480 Arsenal Way, Watertown, MA, United States, 02472

617 207 8979

74

Name Title Year Born
Dr. Peter Blume-Jensen M.D., Ph.D. Co-Founder, Chairman, CEO, Pres & Acting Chief Scientific Officer 1962
Ms. Kristina Masson Ph.D. Co-Founder, Exec. VP of Bus. Operations, Treasurer, Sec. & Director 1980
Dr. Eric J. Devroe Ph.D. Chief Operating Officer 1978
Mr. Erick Gamelin M.D., Ph.D. Chief Medical Officer 1957
Mr. Rasmus Holm-Jorgensen Chief Financial Officer 1971
Ms. Katharine Peterson CPA VP of Fin. & Accounting NA
Mr. Bruce Close VP of Quality & Compliance NA
Ms. Mary-Alice Miller J.D. Gen. Counsel 1974
Ms. Crystal Mercado Global Head of HR NA
Dr. Jesper V. Olsen Ph.D. Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…